AstraZeneca may have included outdated information in Covid vaccine trial, U.S. health agency says
LONDON — A U.S. health agency said Tuesday that AstraZeneca may have included outdated information in trial results of its Covid-19 vaccine, potentially casting doubt over published efficacy rates. The Data Safety Monitoring Board "expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data," the U.S. National Institute of Allergy and Infectious Diseases said in a statement. "We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible." "We will immediately engage with the independent data safety monitoring board (DSMB) to share our primary analysis with the most up to date efficacy data. Shares of AstraZeneca slipped nearly 1% during Tuesday trading in London and were down 2% in premarket trading in New York.cnbc.com
UK is first to authorize easy-to-handle AstraZeneca vaccine
FILE - This undated file photo issued by the University of Oxford on Monday, Nov. 23, 2020, shows of vial of coronavirus vaccine developed by AstraZeneca and Oxford University, in Oxford, England. The Medicines and Healthcare Products Regulatory Agency, which recommended the AstraZeneca vaccine for emergency use, did not endorse one vaccine over the other. Britain’s action likely means the World Health Organization could soon clear the AstraZeneca vaccine for use in a global effort to help poor countries, called COVAX. The European Medicines Agency said it is still assessing the AstraZeneca vaccine and has asked the company for more information on its quality, safety and effectiveness. In addition to the Serum Institute, AstraZeneca has deals with vaccine makers in Brazil, South Africa and China.
Astrazeneca, Oxford University says COVID-19 vaccine 62 to 90% effective depending on dosage
After a Phase 3 trial, officials said a vaccine from Oxford University and Astrazeneca pharmaceutical company is up to 90% effective. The results were based on trials in the United Kingdom and Brazil before the trials start in the United States. When the vaccine was given as a half dose followed by a full dose at least a month later, it was 90% effective. READ: FDA grants emergency use authorization for Regeneron’s COVID-19 antibody cocktailKaul said the University of Michigan has been enrolling patients in the trial for several weeks now. “While there’s a lot of controversy around vaccines, there really isn’t any controversy around vaccines in the medical community.